300 genes found at the root of cancers could spur more personalized treatments
A 10-year-long study called the PanCancer Atlas is releasing a trove of genetic data in an effort to help doctors treat a wide variety of cancers more precisely.
The history: Over the past decade, 150 researchers from the US and around the world painstakingly analyzed DNA, RNA, and proteins from tumor samples of more than 11,000 patients with 33 different types of cancer.
The findings: From that data, scientists have identified about 300 genes that drive tumor growth. They also found that just over half the tumors samples analyzed carry genetic mutations that could be targeted by therapies that are already on the market. These findings and others appear in 29 different papers today in the journal Cell.
Why it matters: Researchers say the insights gleaned can be used to tailor more personalized treatments for cancer patients. “This analysis provides cancer researchers with unprecedented understanding of how, where, and why tumors arise in humans, enabling better-informed clinical trials and future treatments,” says Francis Collins, director of the US National Institutes of Health, which funded the project.
Deep Dive
Biotechnology and health
How scientists traced a mysterious covid case back to six toilets
When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.
An AI-driven “factory of drugs” claims to have hit a big milestone
Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology
The quest to legitimize longevity medicine
Longevity clinics offer a mix of services that largely cater to the wealthy. Now there’s a push to establish their work as a credible medical field.
There is a new most expensive drug in the world. Price tag: $4.25 million
But will the latest gene therapy suffer the curse of the costliest drug?
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.